Lexeo Therapeutics (LXEO) Operating Leases (2022 - 2026)

Lexeo Therapeutics has disclosed Operating Leases across 5 years of filings, most recently posting $4.5 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $4.5 million, down 26.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (down 26.13% YoY), and the FY2025 annual result was $4.9 million, down 24.13% from the prior year.
• Operating Leases came in at $4.5 million for Q1 2026 at Lexeo Therapeutics, down from $4.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.0 million in Q4 2022 to a low of $4.5 million in Q1 2026.
• The 5-year median for Operating Leases is $6.6 million (2024), against an average of $6.6 million.
• Across the five-year window, Operating Leases slipped 13.49% in 2023 and dropped 26.13% in 2026, its largest moves.
• Lexeo Therapeutics' Operating Leases stood at $9.0 million in 2022, then dropped by 13.49% to $7.8 million in 2023, then slipped by 17.33% to $6.4 million in 2024, then declined by 24.13% to $4.9 million in 2025, then retreated by 8.44% to $4.5 million in 2026.
• The last three Operating Leases figures came in at $4.5 million (Q1 2026), $4.9 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.